Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from the line of Charles Duncan of JMP Securities. Please proceed with your question.
Charles Duncan - JMP Securities
Hi, guys. Good morning and congratulations on a very good quarter. My question is regarding perhaps the breadth of potential use of BRAC analysis. If you look at some of the recent literature, suggest that BRAC mutations may convey therapeutic benefit or prognostic information beyond breast cancer, including perhaps prostate cancer. Do you have a sense of the timing of some of the clinical data that could come out including that from the PARP inhibitor studies that could help us better understand the breadth of utility for BRAC analysis, Pete?
Peter Meldrum
Thank you, Charles. You’re absolutely correct. In addition to being the major causes of hereditary breast and ovarian cancer, the BRAC1 and BRAC2 genes have been linked to a number of other cancers, including pancreatic cancer and prostate cancer and colon cancer. We’re very excited about these findings and the company is certainly going to pursue those in the future.
You also pointed out that we do have a collaboration with AstraZeneca to stratify their patient population for their clinical trials for PARP inhibitors. Being DNA repair genes, the BRAC1 and BRAC2 function when it’s lost makes the tumors particularly susceptible to DNA damaging agents like the PARP inhibitors and we’re very excited about the potential of BRAC analysis becoming a companion diagnostic.
So while we continue to exploit our existing markets in breast and ovarian cancer, I think the future looks very good for BRAC analysis to expand to other applications of both personalized medicine and predictive medicine in other types of cancers.
Charles Duncan - JMP Securities
Thanks, Pete.
Operator
Our next question comes from the line of Ed Tenthoff of Piper Jaffrey. Please proceed with the question.
Ed Tenthoff - Piper Jaffrey
Great, thank you very much and congratulations on really a phenomenal quarter. Digging in maybe a little bit on to the performance in this quarter, can you give us a sense of how much of this was benefit from the DTC campaign? How much of this was still continued strength through the Northeast, that analysis on the last direct-to-consumer ad campaign that was very helpful? How of this was growth from some of the other tests beyond BRAC? Give us a little bit more color on what lead to this really record growth?
- To read the full transcript on Seeking Alpha, click here »
